Topics

Articles

Concerns over efficacy and politics clouds hope for a vaccine to end the COVID-19 pandemic.

In an open letter, CEO Albert Bouria sought to give clarity to the drug’s development timeline.

The trial had been halted due to a side-effect in an English patient.

The pledge seeks to assuage fears that the Trump administration will rush a vaccine into production for political purposes.

In a letter, the agency pushes states to fast-track permitting and licensing for possible distribution sites.

The ACP says that staying up to date on vaccinations is more important than ever.

A trio of experts will discuss the prospects of a handful of COVID-19 vaccine candidates which are entering phase 3 trials.

The deal is for the companies to supply up to 600 million doses of a MRNA-based vaccine candidate.

The candidate is a joint effort of Oxford University and AstraZeneca.

In a 45-person phase one clinical trial the vaccine subjects who received the vaccine candidate showed high neutralizing antibody responses.